A Study to Determine Number of Patients Who Develop High Ammonia Levels After Receiving Recombinant Erwinia Asparaginase
Launched by MAYO CLINIC · Sep 16, 2024
Trial Information
Current as of July 12, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is looking at how many patients develop high levels of ammonia in their blood after receiving a treatment called recombinant Erwinia asparaginase, which is used to help fight certain blood cancers like acute lymphoblastic leukemia. High ammonia levels can cause symptoms that may be concerning, so the study aims to understand how often this happens in patients receiving this medication.
To participate in the trial, patients need to be followed by a pediatric hematology/oncology team and must be receiving recombinant Erwinia asparaginase as part of their cancer treatment. Unfortunately, children under one year old or those who have received this treatment in the last two weeks cannot take part. If eligible, participants will be monitored during their treatment to see if they experience any symptoms related to high ammonia levels. This study is currently recruiting participants, and it aims to improve our understanding of the safety of this important cancer therapy.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Followed by pediatric hematology/oncology
- • Receiving recombinant Erwinia asparaginase for treatment of malignancy
- Exclusion Criteria:
- • Patients \< 1 year of age
- • Patients who have previously received recombinant Erwinia asparaginase within the past two weeks
About Mayo Clinic
Mayo Clinic is a renowned nonprofit medical practice and research institution dedicated to providing comprehensive healthcare and advancing medical knowledge through innovative research and education. With a commitment to patient-centered care, Mayo Clinic conducts numerous clinical trials aimed at exploring new therapies and improving treatment outcomes across various disciplines. Leveraging a multidisciplinary approach, the institution collaborates with leading experts and cutting-edge technology to ensure rigorous scientific standards and ethical practices in all its research endeavors. Through its trials, Mayo Clinic seeks to translate breakthroughs in science into tangible benefits for patients, fostering advancements in medicine that enhance health and quality of life.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Rochester, Minnesota, United States
Patients applied
Trial Officials
Catherine E. Martin, PharmD, RPh
Principal Investigator
Mayo Clinic in Rochester
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported